Current Report Filing (8-k)
16 Fevereiro 2022 - 7:16PM
Edgar (US Regulatory)
0001630113
false
0001630113
2022-02-14
2022-02-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): February 14, 2022
BIOTRICITY
INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
000-56074 |
|
30-0983531 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
203 Redwood Parkway, Suite 600
Redwood City, California 94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
BTCY |
|
The
NASDAQ Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations
and Financial Condition |
On
February 14, 2022, Biotricity, Inc. (the “Company”) issued a press release reporting certain unaudited financial results
for the fiscal quarter ended December 31, 2022. The full text of this press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
Pursuant
to General Instruction B.2. to Form 8-K, the information set forth in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall any of them be incorporated by reference in any filing under the Securities Act of 1933,
as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item
9.01 |
Financial
Statements and Exhibits |
(d)
Exhibits. The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date:
February 16, 2022
| |
BIOTRICITY
INC. |
| |
|
|
| |
By: |
/s/
John Ayanoglou |
| |
|
John
Ayanoglou
|
| |
|
Chief
Financial Officer |
Biotricity (QB) (USOTC:BTCY)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Biotricity (QB) (USOTC:BTCY)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
